The government hopes to limit cases in which NICE determines a treatment isn't cost effective after the MHRA has deemed it ...

A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.

Early clinical data indicates the treatment leads to dose-dependent increases in functional AAT protein, which is altered in the condition.

BriGene Biosciences supported Grit with technology transfer, manufacturing, and regulatory requirements for the IND for GT307.

In the third phase, the Diagnostics Accelerator will support the development of multi-marker panels leveraging digital and AI tools that can accelerate precision treatments.

The firm originally submitted the application seeking approval for TLX101-Px in August 2024, but the agency requested additional efficacy analysis.

Sarepta plans to evaluate the gene therapy with a new immunosuppressive regimen in the hopes of relaunching it in the non-ambulatory indication.

The next question researchers want to answer is whether urine-derived lymphocytes can actually help inform responses to ...

NEW YORK – Sellas Life Sciences has enrolled the first patient in a Phase II trial of its CDK9 inhibitor tambiciclib in first-line acute myeloid leukemia (AML), the company announced this week. The ...

NEW YORK – Pierre Fabre Pharmaceuticals on Thursday said it will meet with the US Food and Drug Administration to address the complete response letter it received on its application seeking approval ...

NEW YORK – Novartis' key patent on its radioligand therapy Lutathera (lutetium Lu 177 dotatate) isn't set to expire until 2038, but radiopharmaceutical company Lantheus is already preparing to ...